EVOLUTION OF THE TREATMENT FOR CHRONIC HEPATITIS C
Abstract
Hepatitis C virus was discovered in 1989. For a long time, interferon α2 and ribavirin were the only therapeutical option available for the antiviral treatment of chronic hepatitis C. During recent years, novel interferon-free regimens have been developed. These regimens consist of the direct-acting agents, which are potent inhibitors of the key proteins in the viral replication cycle. Compared to the interferon-based treatment, these direct-acting agents provide greater efficacy and better safety profile.
References
1. Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection / B. R. Bacon [et al.] // New England Journal of Medicine. – 2011. – Vol. 364, № 13. – P. 1207-1217.
2. Cholongitas, E. Sofosbuvir: A Novel Oral Agent for Chronic Hepatitis C / E. Cholongitas, V. George // Annals of Gastroenterology. – 2014. – Vol. 27, № 4. – P. 331-337.
3. Association of TNF-α and CCL5 with response to interferon-based therapy in patients with HCV 1 genotype / D. Danilau [et al.] // Clinical and Experimental Hepatology. – 2017. – Vol. 3, № 1. – P. 16-22.
4. Hepatitis C FAQs for Health Professionals [Electroniс resource]. – Mode of access: http://www.cdc.gov/hepatitis/hcv/hcvfaq.htm. – Date of access: 25.04. 2017.
5. Comparison of peginterferon alfa-2a and alfa-2b for treatment of patients with chronic hepatitis C: a retrospective study using the Japanese Interferon Database / Y. Kawasaki [et al.] // Drug Design, Development and Therapy. – 2015. – Vol. 9. – P. 283-290.
6. Hepatitis C virus infection / M. P. Manns [et al.] // Nature Reviews Disease Primers. – 2017. – № 3. – S. 17006.
7. Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence / K. Mohd Hanafiah, J. Groeger, A. D. Flaxman, S. T. Wiersma // Hepatology. – 2013. – Vol. 57, iss. 4. – P. 1333-1342.
8. An updated analysis of hepatitis C virus genotypes and subtypes based on the complete coding region / T. Nakano [et al.] // Liver International. – 2012. – Vol. 32, iss. 2. – P. 339-345.
9. Paritaprevir/ritonavir/ombitasvir plus Dasabuvir with Ribavirin for Chronic Hepatitis C // Australian Prescriber. – 2016. – Vol. 39, iss. 4. – P. 141-143.
10. Phase 3 Studies Show Simeprevir plus Interferon/ Ribavirin Cures Most Patients in 24 Weeks [Electroniс resource]. – Mode of access: http: // www.hivandhepatitis.com/hepatitis-c/ hepatitis-c-topics/hcv-treatment/3926-phase-3-studies-showsimeprevir-plus-interferonribavirin-cures-most-patients-in-24- weeks. – Date of access: 24.04.2017.
11. Boceprevir for Untreated Chronic HCV Genotype 1 Infection / F. Poordad [et al.] // New England Journal of Medicine. – 2011. – Vol. 364, № 13. – P. 1195-1206.
12. Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C / Y. Tanaka [et al.] // Nature Genetics. – 2009. – Vol. 41, № 10. – P. 1105-1109.
13. The European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2014 [Electroniс resource]. – Mode of access: http://www.easl.eu/_clinical-practice-guidelin. – Date of access: 24.04.2017.
14. Thrift, A. P. Global epidemiology and burden of HCV infection and HCV-related disease / A. P Thrift, H. B. El-Serag, F. Kanwal // Nature Reviews Gastroenterology & Hepatology. – 2017. – Vol. 14, № 2. – P. 122-132.
15. Gasich, E. L. Genetic diversity of Hepatitis С virus in Belarus / E. L. Gasich, V. F. Eremin // Zdravoohranenie. – 2016. – № 10. – P. 24-29. (Russian)
16. Gepatit С [Jelektronnyj resurs] : informacionnyj bjulleten' (Ijul', 2016 g.) // Vsemirnaja organizacija zdravoohranenija. – Rezhim dostupa: http://www.who.int/mediacentre/factsheets/fs164/ru/. – Data dostupa: 25.04.2017. (Russian)
17. Additional predictors of efficacy of treatment for chronic hepatitis C 1 genotype with IFN-based regimens (sustained virological response). Ch. 2 / D. E. Danilau [et al.] // Zdravoohranenie. – 2016. – № 8. – P. 4-9. (Russian)
18. Additional predictors of efficacy (end-of-treatment response) of treatment for chronic hepatitis C 1 genotype with IFNbased regimens. Ch. 1 / D. E. Danilau [et al.] // Zdravoohranenie. – 2016. – № 7. – P. 10-18. (Russian)
19. Clinical experience of treatment of chronic genotype 1 hepatitis C with 3D regimen in Belarus / D. E. Danilau [et al.] // Retsept. – 2016. – № 6. – P. 675-682. (Russian)
20. Jeffektivnost' lechenija hronicheskogo virusnogo gepatita С preparatami interferona v sochetanii s ribavirinom / D. E. Danilov [i dr.] // Aktual'nye voprosy gepatologii : jeksperimental'naja gepatologija, terapevticheskaja gepatologija, hirurgicheskaja gepatologija : materialy 10-go Mezhdunarodnogo simpoziuma gepatologov Belarusi, Grodno, 26-27 sentjabrja 2013 g. / redkol.: V. M. Cyrkunov (otv. red.) [i dr.] – Grodno, 2013. – S. 30-32. (Russian)
21. Novye dannye o gepatite svidetel'stvujut o neobhodimosti bezotlagatel'nyh global'nyh dejstvij [Jelektronnyj resurs] // Vsemirnaja organizacija zdravoohranenija. – Rezhim dostupa: http://www.who.int/mediacentre/news/releases/2017/globalhepatitis-report/ru/ – Data dostupa: 25.04.2017. (Russian)
1.png)
